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Paget’s disease of the bone (PDB) is a common skeletal disorder caused by focal abnormalities of the bone remodelling process which leads which can present with various features including bone pain, bone deformity, deafness, pathological fractures and rarely osteosarcoma.  Several rare inherited bone disorders have also been described that show phenotypic overlap with classical PDB but which have an earlier age at onset and which are more severe. They include familial expansile osteolysis (FEO)  ADDIN EN.CITE [1] expansile skeletal hyperphosphatasia (ESH) [2] Early-onset familial Paget’s disease  ADDIN EN.CITE [3], Juvenile Paget’s disease [4], and panostotic expansile bone disease  ADDIN EN.CITE [5]. In addition, classical PDB is recognised to be a component of rare inherited syndromes with non-skeletal features including inclusion body myopathy, frontotemporal dementia, and amyotrophic lateral sclerosis disease  ADDIN EN.CITE [6]. 
The disorders discussed in this review are mostly inherited in an autosomal dominant manner in which the PDB-like component is variably penetrant, although Juvenile PDB is an autosomal recessive condition. In general, the PDB component in these disorders has an earlier age of onset than classical PDB and in in the case of the syndromes caused by TNFRSF11A and TNFRSF11B mutations is much more severe.  The presentation, clinical features, pathogenesis and management of classical PDB are discussed by Gennari in an accompanying article in this issue [7].
Inherited Expansile Osteolytic syndromes
These disorders are characterised clinically by early onset deafness, premature tooth loss and expansile bone lesions predominantly affecting the axial skeleton. They are caused by insertion mutations of between 12 and 27 base pairs within the first exon of TNFRSF11A which encodes the Receptor Activator of Nuclear Factor Kappa B (RANK) (Figure 1). Current evidence suggests that these mutations inhibit or prevent cleavage of the RANK signal peptide causing the abnormal protein to accumulate in the Golgi apparatus which in turn causes activation of NFB signalling through the unfolded protein response (Figure 2). There is considerable heterogeneity of clinical phenotype in subjects with different mutations and in those who carry the same mutation both between and within families. In this review, the individual disorders are discussed on the basis of clinical phenotypes which are summarised in Table 1. 


Table 1. Spectrum of phenotypes associated with insertion mutations in TNFRSF11A.







Disease onset 	Childhood	Adolescence	Infancy 	Adolescence	Infancy









Radius / ulna 	++	+	+	++	+
Carpal/ Tarsal 	-	+		+	+
Phalanges	-	+	+	++	+
Frequency of involvement is indicated by: seldom/never involved (-), sometimes involved (+), often involved (++).
Familial Expansile Osteolysis
Clinical features
In 1988, Osterberg and colleagues  ADDIN EN.CITE [1] coined the term “familial expansile osteolysis” (FEO; MIM 174810) to describe a bone dysplasia characterised by the presence of focal expansile bone lesions predominantly affecting the lower limbs, accompanied by bone pain, deformity   and pathological fractures. In fact, a similar disorder affecting two brothers had been described about 10 years earlier by Enderle and Willert [8].
The initial presentation of the disorder in affected members of the family described by Osterberg was with hearing loss, initially of a conductive type during the first or second decade, which subsequently evolved into a mixed sensorineural type of deafness. The cause of the deafness was attributable to damage of the bones of the middle ear. A characteristic feature on otological examination was replacement of the incus by fibrous tissue. Musculoskeletal manifestations of the disease include deformity and bone pain predominantly affecting the appendicular skeleton. Common sites of involvement were the tibia, fibula and humerus. Pathological fractures were common and reported to occur in 12 of 97 lesions observed (12.4%). Dental abnormalities were also common, presenting with excessively mobile teeth, fractured teeth and premature tooth loss in the second decade. Further reports of FEO were later published affecting individuals from Spain [9] and the USA  ADDIN EN.CITE [10, 11]. The clinical presentation in a three-generation Spanish family reported by Palenzuela and colleagues [9] was with deafness during the first decade, followed by tooth loss and other dental problems in the second decade. It is of interest that focal osteolytic lesions were not prominent in this family and occurred in only two of the subjects studied. In contrast, expansile osteolytic lesions were a prominent feature in affected members of a five-generation family reported by Whyte [11]. The proband first presented age 63 with a pathological fracture of the humerus occurring at the site of a lytic lesion but there was no history of early onset deafness or early tooth loss. Of the eight affected family members where data were available, 6 (75%) had expansile osteolytic lesions; 6 (75%) had early-onset deafness but only 1 (12.5%) had early tooth loss. In another study, Johnson-Pais  ADDIN EN.CITE [10] reported the phenotype of two unrelated individuals with FEO, both had early onset deafness and premature tooth loss and both had osteolytic lesions. 
Focal and generalized abnormalities of bone have both been described in patients with FEO. Osterberg commented that abnormalities in the trabecular pattern of bone on x-rays could be identified affecting the humerus, radius, ulna and tibia, before osteolytic lesions develop.  The focal osteolytic bone lesions which developed in Osterberg’s family most commonly affected the tibia (31%), radius (11%), fibula (10%), humerus (9%) and femur (9%)  ADDIN EN.CITE [1]. In contrast to classical PDB, the pelvis, spine and skull were unaffected. The rate at which the lytic bone disease advanced in the long bones was estimated to be 10-18mm per year which is much more rapid that in classical PDB  ADDIN EN.CITE [1]. Radionuclide bone scans show increased tracer uptake at the site of focal osteolytic lesions. In addition, tracer uptake was reported to be increased in the tibiae of patients without focal bone lesions in keeping a generalized elevation in bone turnover. Biochemical evaluation of affected patients showed elevated circulating concentrations of total alkaline phosphatase (ALP) and hydroxyproline consistent with a state of high bone turnover. 
The clinical features of FEO are entirely consistent with dysregulation of osteoclast activity. Although bone formation is also increased, as reflected by the elevations in ALP concentrations this is thought to be the result of coupling between bone resorption and formation as occurs in classical PDB. Although there are many similarities between FEO with PDB, the severity and pattern of skeletal involvement in these two disorders are distinct.  
Genetics
The gene responsible for FEO in the family described by Osterberg was localised to chromosome 18q21 by Hughes are colleagues  ADDIN EN.CITE [12]. Subsequently, mutations in exon 1 of the TNFRSF11A gene were identified as the cause of FEO  ADDIN EN.CITE [13]. The TNFRSF11A gene encodes Receptor Activator of NFκB (RANK)  ADDIN EN.CITE [14] which plays a critical role in osteoclast differentiation and function when activated by its ligand RANK ligand (RANKL)  ADDIN EN.CITE [15]. The causal mutation in FEO was found to be a 18-bp duplication at position 84 of exon 1 (84dup18) that segregated with the disease in all affected family members and in the families described by Whyte [11] and one affected individual described by Enderle and Willert [8]. Subsequently the same mutation was identified in the FEO patients described by Johnson-Pais  ADDIN EN.CITE [10] and Palenzuela [9]. This region of TNFRSF11A consists of a repeated GC-rich sequence (Figure 1), raising leading the possibility that slippage during the process of recombination resulted in the duplication. 
Pathophysiology
The 84dup18 mutations is predicted to elongate the RANK signal peptide by six amino-acids and bio-informatic studies coupled with studies of human embryonic kidney cells (HEK239) cells transfected with wild type and mutant RANK proteins showed that the mutations prevented cleavage of the signal peptide  ADDIN EN.CITE [13, 16]. These studies also showed that the mutant protein was expressed at a lower level than wild type. Transient expression of the 84dup18 mutation in the same cells showed increased activation of an NFB reporter vector when compared with wild type RANK but only when the levels of expression were corrected for the lower amounts of protein present with the 84dup18 mutation  ADDIN EN.CITE [13]. Crockett and colleagues subsequently performed a series of studies to further elucidate the mechanisms by which the 84dup18 insertion mutation caused osteoclast activation  ADDIN EN.CITE [16]. At the same time Crockett investigated the functional effects of the 75dup17 and 84dup15 mutations which cause the related disorders of early onset familial PDB  ADDIN EN.CITE [3] and expansile skeletal hyperphosphatasia [2] (discussed later in this review).  These experiments confirmed that the all three mutations prevented signal peptide cleavage and also showed that over-expression of wild type and mutant RANK proteins activated NFB signalling in vitro. Crockett further demonstrated that the mutant RANK proteins were not expressed at the cell membrane as they should be, but instead became trapped in the endoplasmic reticulum (ER). It was also found that when the mutant proteins were stably expressed as a single copy in HEK293 cells, they did not cause constitutive activation of RANK signaling. On the contrary cells expressing the mutant proteins were unable to increase NFκB signalling when stimulated with RANKL. This led Crockett to the conclusion that these were loss-of-function mutations with regard to RANKL induced RANK signaling. Support for the concept that the insertion mutations are loss-of-function in terms of classical RANKL-RANK signaling comes from the observation presented so far in abstract form only, that mice homozygous for the 75dup27 mutation exhibit an osteopetrotic phenotype with absence of functioning osteoclasts [17]. The conundrum remains as to why these mutations are associated with osteoclast activation and high bone turnover in vivo. This has not yet been fully explained but the authors speculated  ADDIN EN.CITE [16] that the osteoclast activation seen in this and related mutations may be due to ligand independent activation of NFκB as the result of the mutant proteins being resident in the ER [18] .
Management
Medical management of FEO has focused on the use of osteoclast inhibitors. Affected members of the family described by Osterberg have been treated at various points with calcitonin, dichloromethylene bisphosphonate and pamidronate [19]. Calcitonin and dichloromethylene bisphosphonate were reported to give biochemical improvement as reflected by reductions in markers of bone turnover and clinical improvement in terms of bone pain but this was reported to be short lived. Intravenous pamidronate was reported to give a more sustained clinical and biochemical improvement in affected family members with evidence in some cases of remineralisation of the osteolytic lesions [19]. The long-term effects of these drugs on the natural history of FEO remains unclear 
Expansile Skeletal Hyperphosphatasia 
Clinical features
The term “expansile skeletal hyperphosphatasia” was coined by Whyte and colleagues to described an inherited osteolytic disorder affecting a mother and her 13 year-old daughter, [2]. Both individuals had presented with early onset deafness and premature tooth loss. Subsequently bone involvement became more prominent with hyperostotic expansion of several long bones and particularly the phalanges of the hands. Hypercalcaemia was reported during lactation and periods of immobilization in the mother. Serum alkaline phosphatase and other markers of bone turnover were elevated in both affected individuals. Genetics 
Genetic analysis showed that the disorder was caused by a 15bp duplication at position 84 (84dup15) in TNFRSF11A affecting the signal peptide of RANK. 
Pathophysiology
The pathophysiology of this disorder was investigated by Crockett  ADDIN EN.CITE [16] and is thought to be similar to that of FEO and early onset familial PDB; namely, failure of signal peptide cleavage of RANK with sequestration of the protein in the endoplasmic reticulum and activation of NFB signaling through accumulation of the abnormal protein in the ER.
Management
The mother received treatment with calcitonin, etidronate and pamidronate; all three treatments reduce biochemical markers if bone turnover and (in the case of the mother) improved hypercalcaemia but the authors reported that they had little effect on bone pain. 
Early-onset familial Paget’s disease
Clinical features
This autosomal dominant disorder has so far been reported in one family of Japanese descent  ADDIN EN.CITE [3]. The initial presentation in affected family members was with hearing loss in the first to second decade followed by premature tooth loss in the second to third decade, Musculoskeletal symptoms including bone pain and deformity developed subsequently. This disease affected both the axial and appendicular skeleton. Radionuclide bone scan examination showed increased tracer uptake in affected bones and radiographs showed mixed osteolytic and osteosclerotic lesions reminiscent of classical PDB. Two affected individuals had striking involvement of the maxilla and the mandible. Biochemical investigations showed markedly elevated levels of ALP and one patient developed an episode of hypercalcaemia during a period of immobilization. A second family of Chinese origin with a similar disorder was described by Ke and colleagues  ADDIN EN.CITE [20] . In this family the presentation was with expansile bone lesions in a distribution similar to that reported in the Japanese family accompanied by deformity, pain and pathological fracture. In one patient however, the only manifestation was evidence of increased bone turnover.  The authors did not mention whether the affected patients had suffered deafness or premature tooth loss. 
Genetics
The cause of the disorder in the Japanese family  ADDIN EN.CITE [3] was found to be a 27bp duplication within exon 1 of the TNFRSF11A gene  ADDIN EN.CITE [13]. In the Chinese family  ADDIN EN.CITE [20] there was a similar 27bp duplication but starting at position 78 (78dup27) instead of 75.
Pathophysiology
As in the case of the FEO mutation, this duplication was found to prevent cleavage of the signal peptide of RANK, causing accumulation of the abnormal protein in the ER  ADDIN EN.CITE [16].  
Management
Affected patients in the Japanese family were treated with various antiresorptive drugs including etidronate, pamidronate, risedronate and calcitonin. Etidronate treatment given to three patients reduced biochemical markers of bone turnover but did not normalize them. Pamidronate and risedronate were reported to be more effective than etidronate at reducing markers of bone turnover. One patient treated with pamidronate reported an improvement in bone pain. There was no discernable effect of treatment on deafness or bone deformity in any patient. One patient in the Chinese family was treated with intravenous ibandronate which normalized ALP although the effects on pain were not reported.  
Juvenile PDB
A female individual with an early onset PDB like syndrome due to a TNFRSF11A mutation has been described  ADDIN EN.CITE [21]. The presentation was with tooth loss and hearing loss and low trauma fractures of the tibia and fibula at aged 2 but the patient was also noted to have femoral deformity by ultrasound in utero.  At aged 4 years the patient was immobilized following a fracture and developed hypercalcaemia. Biochemical markers of bone turnover were markedly elevated. Radionuclide bone scan at aged 3 revealed increased tracer uptake affecting several bones and radiographs showed changes that were thought to be consistent with juvenile PDB. However, genetic analysis excluded the presence of mutations in TNFRSF11B and instead the patient was found to have a heterozygous 15bp insertion mutation at position 87 in exon 1 of TNFRSF11A (87dup15). Although the mutation is the same size as the 15bp mutation causing FEO, the sequence change is slightly different as is the site of insertion (Figure 1). The pathogenesis is likely to be the same as in the other conditions with TNFRSF11A insertion mutations. The patient was treated pamidronate between the age of 4 and 11 years. This reduced biochemical markers of bone turnover this didn’t appear to modify progression of deafness or tooth loss. The patient wasn’t reported to have pain either before or after pamidronate.
Panostotic expansile bone disease
The term “panostotic expansile bone disease“ was coined to describe the clinical phenotype in a 32-year-old man who presented with an expansile bone disease affecting virtually the whole skeleton accompanied by a massive benign tumour affecting the mandible and benign tumours of the maxilla  ADDIN EN.CITE [5]. 
The initial presentation was with congenital deafness but subsequently the patient developed bone deformity of the lower limbs from the aged of about 4 years. The patient was edentulous and his mother reported that his deciduous teeth were never replaced by permanent teeth. From the age of 12 years he suffered multiple fragility fractures after minimal trauma. The mandibular tumour developed during his teenage years and he was hospitalised on several occasions for anaemia secondary to bleeding from this tumour which was found on histological examination to show features of a benign fibro-osseous tumour. 
The patient also developed a tumour affecting the maxilla and there was a history of recurrent renal stones. The patient suffered widespread bone pain.  Biochemical studies showed greatly elevated levels of total serum alkaline phosphatase as well as bone specific alkaline phosphatase. He had hyperuricaemia in the presence of normal renal function. Urinary calcium excretion was not elevated. 
Genetics
Genetic analysis showed that the disorder was caused by a 12bp duplication at position 84 (84dup12) in TNFRSF11A affecting the signal peptide of RANK. (Figure 1). The pathophysiology of this disorder has not been investigated but the authors of the report speculated that it was likely to be failure of signal peptide cleavage of RANK as had been described for other mutations in this region. 
Management
The patients jaw lesions were treated successfully by surgery. Prior to this he was treated with alendronate which reduced biochemical markers of bone turnover to near normal levels but which also caused hypocalcaemia despite the fact that calcium and vitamin D supplements were given. Pamidronate therapy at lose dose (10mg, intravenously) was subsequently used to supress bone turnover along with calcium and vitamin D supplements. Although the patient responded well in terms of biochemical markers, his clinical response was disappointing with little or no improvement in bone pain (personal communication, Dr Anne Schafer)
Juvenile Paget’s disease 
Juvenile Paget’s disease (JPD) (MIM 239000) is a rare, autosomal  recessive disorder which was originally described in the 1950’s [4]. Other names for the condition include Idiopathic Hyperphosphatasia and Familial Hyperphosphatasemia. The disease is characterised by markedly increased bone turnover; skeletal deformities reminiscent of classical PDB, bone expansion, bone pain, and an increased risk of pathological fractures. 
Clinical features 
The presentation is during infancy or childhood with skeletal deformity, growth retardation and failure to thrive. Other clinical features include; enlargement of the skull, immobility or difficulty in walking, progressive sensorineural deafness, kyphosis and acetabular protrusion. The phenotype is variable, depending on the type of mutation. Chong and colleagues  ADDIN EN.CITE [22] suggested a simple clinical classification for the disorder based on age at onset, mobility and height (Table 2). 
Table 2. Clinical classification of severity in JPD
	Mild	Moderate	Severe




In all except the very mildest cases of JPD bone deformity increases during adolescence and this is often accompanied by loss of mobility. Interestingly, fractures occur more commonly in patients with a mild or intermediate phenotype, presumably because they are more mobile  ADDIN EN.CITE [22]. Extra-skeletal manifestations may become prominent later in life. Most patients develop a retinopathy by the second decade. This is detectable on fundoscopy by the appearance of angioid streaks, pallor of the optic disc, peripapillary atrophy and evidence of choroidal neovascularization. Vascular calcification is another recognised feature which becomes more penetrant with increasing age. Aneurysms of the internal carotid artery have also been reported [23]. Other features which have been reported include contractures, which seem most likely to be secondary to deformity, sinus aplasia, hormone deficiencies and hypertension [24]. Difficulties with intubation have been reported due to calcification of tracheal cartilage [25]. Auricular calcification may also occur  ADDIN EN.CITE [26]. Concentrations of serum alkaline phosphatase, and other markers of bone turnover are greatly elevated in JPD, reflecting the generalised increase in the rate of bone remodelling. The bones are enlarged with radiological features reminiscent of PDB. Serum concentrations of OPG are not helpful in diagnosis; while circulating OPG concentrations are undetectable in some patients; others have normal values and elevated values have been reported in patients that carry the so-called Balkan mutation which causes a frameshift in exon 5  ADDIN EN.CITE [27].  
Genetics
Juvenile PDB is most commonly caused by recessive loss-of-function mutations in the TNFRSF11B gene which encodes osteoprotegerin, although a similar phenotype has been reported in a patient with a mutation of TNFRSF11A  ADDIN EN.CITE [21] as discussed in the previous section of this article. Osteoprotegerin is a member of the TNF-receptor superfamily, which acts as a soluble decoy receptor for RANK-ligand, blocking osteoclast activation and bone resorption  ADDIN EN.CITE [15]. Deficiency of OPG in JPD was first reported by Whyte and colleagues who described two Navajo patients with JPD with undetectable circulating concentrations of OPG. Genetic analysis revealed a homozygous deletion of the TNFRSF11B gene as the cause of the disorder  ADDIN EN.CITE [28]. Subsequently, Cundy and colleagues described a family of Iraqi origin, in which three of nine siblings had JPD. They found suggestive evidence of linkage to the TNFRSF11B locus on chromosome 8q24.  Mutation screening of TNFRSF11B in this family revealed a homozygous 3bp deletion in all three affected siblings, which was predicted to result in the loss of an aspartate residue that is highly conserved in members of the TNF-receptor superfamily  ADDIN EN.CITE [29]. To-date several disease-causing mutations in TNFRSF11B have been so far identified in JPD, as summarised in Table 3
Table 3. Reported mutations of TNFRSF11B in Juvenile PDB 
Mutation	Predicted functional consequences	Clinical phenotype 	Reference
Deletion of 100Kb encompassing entire gene	Deletion of all exons. No functional OPG produced.	Severe 	Whyte  ADDIN EN.CITE [28]
Deletion affecting TNFRSF11B and 3 other genes	Deletion of all exons. No functional OPG produced.	Severe	Grasemann  ADDIN EN.CITE [30]
Met1Arg 	Start codon disrupted. No functional OPG produced	Severe	Grasemann  ADDIN EN.CITE [30] 
Insertion CTCG exon 1	Frameshift with truncated protein at codon 9. 	Severe	Grasemann  ADDIN EN.CITE [31]
Deletion affecting exon 3/intron 3 	Truncated protein	Severe	Chong  ADDIN EN.CITE [22]
Intragenic deletion of 250kb from intron 1 to downstream of exons	Deletion of exons 2-5. No functional OPG produced	Severe	Naot  ADDIN EN.CITE [32]
Deletion of 20bp affecting exon 3 / intron 3 splice junction	Truncated protein with deletion of exons 4 and 5 	Severe	Chong  ADDIN EN.CITE [22]
Cys44Arg	Disruption of OPG structure through impairment of disulphide bridges	Severe	Saki  ADDIN EN.CITE [33]
Cys65Arg	Disruption of OPG structure through impairment of disulphide bridges	Severe	Chong  ADDIN EN.CITE [22]
Cys87Tyr	Disruption of OPG structure through impairment of disulphide bridges	Severe	Chong  ADDIN EN.CITE [22]
Thr76Pro	Impaired ligand binding	Mild/intermediate	Naot  ADDIN EN.CITE [32]
Phe117Leu	Impaired ligand binding	Intermediate	Chong  ADDIN EN.CITE [22]
DelArg182	Impaired ligand binding; reduced secretion	Intermediate	Cundy  ADDIN EN.CITE [29]




The cause of JPD is deficiency or absence of a fully functional osteoprotegerin which causes unopposed activation of RANK signaling in bone and other tissues, most notably the cardiovascular system. Most of the JPD-associated TNFRSF11B mutations have only been evaluated by in silico techniques for their predicted effects on OPG function. However, Cundy and colleagues conducted a detailed analysis of the functional consequences of the DelArg182 in vitro  ADDIN EN.CITE [29, 35]. They showed that the mutant form of OPG was over-glycosylated; failed to inhibit osteoclastic resorption in organ cultures confirming that the mutation causes loss of OPG function  ADDIN EN.CITE [29, 35]. Secretion of the mutant protein was also found to be defective in various cell culture models leading the authors to conclude that abnormal protein may be retained within the cell and degraded  ADDIN EN.CITE [35].  Subsequent studies by an International collaborative group evaluated nine families with clinical features of JPD and identified homozygous missense mutations of TNFRSF11B in six families with variations in severity depending on the site of the mutations  ADDIN EN.CITE [22]. Within this study, mutations affecting cysteine residues that were predicted to cause disruption of the ligand-binding region, were associated with a severe phenotype; those not affecting cysteine residues in the ligand-binding domain an intermediate phenotype, and an insertion/deletion mutation at the C-terminus a mild phenotype. 
Management
Medical management of JPD has mainly focused on the use of the osteoclast inhibitors calcitonin and bisphosphonates but replacement therapy with osteoprotegerin has also be investigated. Calcitonin was one of the first drugs to be used in the management of JPD [36] although the evidence base it’s use stems exclusively from case reports. These reports indicate that calcitonin can reduce serum ALP concentrations and improve bone pain in JPD  ADDIN EN.CITE [37, 38]. However, calcitonin does not restore normal levels of bone turnover and there is a rapid relapse when treatment is stopped. Because of this, and the availability of bisphosphonates, calcitonin has now been superseded.  Various bisphosphonates have been used in JPD including etidronate [39], alendronate [40], pamidronate  ADDIN EN.CITE [41, 42], ibandronate  ADDIN EN.CITE [43], risedronate  ADDIN EN.CITE [27, 44] and zoledronic acid  ADDIN EN.CITE [44]. All of these drugs have been shown to reduce biochemical markers of bone turnover to varying extent and to improve bone pain. Since the evidence base consists of case reports or small case series, it’s difficult to reach firm conclusions except to note that nitrogen-containing bisphosphonates have given more complete suppression of biochemical markers of bone turnover than non-nitrogen containing bisphosphonates and that higher cumulative doses may be required to control the marked elevations in bone turnover that are observed in this condition. For example, Cundy and colleagues reported that high doses of ibandronate gave effective biochemical control in PDB when standard doses of pamidronate had not worked adequately. Zoledronic acid has also been successfully used to treat JPD but an important adverse event that has emerged with this agent is severe hypocalcaemia  ADDIN EN.CITE [44] which reflects the very potent inhibitory effects that this bisphosphonate has on osteoclastic bone resorption. It is thought that high dose bisphosphonates might help to prevent progression of bone deformity in JPD but there isn’t any firm evidence as yet to show that this strategy is effective in altering the natural history of JPD. 
 In recent years, and the RANKL inhibitor denosumab have been used and found to supress markers of bone turnover in JPD  ADDIN EN.CITE [30, 45].  Severe hypocalcaemia has been reported as an adverse effect with denosumab in this situation  ADDIN EN.CITE [30]. 
Another treatment approach has been the use of recombinant osteoprotegerin  ADDIN EN.CITE [46]. This has the theoretical advantage of addressing the deficiency of osteoprotegerin which underlies JPD  ADDIN EN.CITE [46]. Treatment with osteoprotegerin was successful in inhibiting bone turnover in JPD but the effect wore off soon after treatment was stopped  ADDIN EN.CITE [46].  Currently, this drug is not available for clinical use. 
Multisystem proteinopathy syndromes
Paget’s disease can rarely be inherited as part of a wider syndrome in which other neuromuscular features occur in association with defects in the autophagy pathway and/or accumulation of abnormal protein aggregates in affected tissues. The syndrome can occur in association with mutations in several genes and has been referred to as multisystem proteinopathy (MSP). The first reference to PDB occurring in association with muscle disease that the authors of this review  could find was that of McBride [47] who in 1966 reported a Scottish family in which PDB had been inherited in an autosomal dominant manner, in association with what was considered to be a form of muscular dystrophy. Subsequently, Tucker [48] and then Kimonis  ADDIN EN.CITE [49] described families in which in which Paget’s disease and a limb girdle type of muscular dystrophy were inherited together in an autosomal dominant fashion. The research group of Kimonis extended these observations when they described four families in which myopathy and Paget’s disease had been inherited in association with frontotemporal dementia, thereby delineating, a syndrome which they named inclusion body myopathy, Paget’s disease and frontotemporal dementia (IBMPFD; now known as known as MSP1) (MIM 605382)  ADDIN EN.CITE [50]. The IBMPFD syndrome was localised to chromosome 9p13 by linkage analysis  ADDIN EN.CITE [50] and subsequent positional cloning studies revealed that missense mutations in the VCP gene, encoding Valosin containing protein were the cause of the disorder  ADDIN EN.CITE [51]. As early as 2002 it was recognised that not all families with this syndrome were linked to 9p13, indicative of genetic heterogeneity  ADDIN EN.CITE [52]. Subsequent genetic analysis of families affected by PDB, myopathy and neurodegenerative disease in whom VCP mutations were not identified showed that mutations in the hnRNPA2B1 and hnRNPA1 genes may also cause the syndrome  ADDIN EN.CITE [6] and that a syndrome with overlapping features could be caused by mutations in the SQSTM1 and OPTN genes, both of which are implicated in classical PDB  ADDIN EN.CITE [53-55]. 
Multisystem Proteinopathy
This rare syndrome was first described as “inclusion body myopathy, Paget’s disease and frontotemporal dementia” (IBMPFD) by Kimonis and colleagues in a series of families from the USA where the disease was inherited in an autosomal dominant fashion [MIM 605382]. Subsequent appreciation of the broader phenotypic spectrum (for example motor neuron disease and parkinsonism) associated with this syndrome led to adoption of a new term, “multisystem proteinopathy” (MSP), to describe these and similar families [56]. 
Clinical features
The initial description was with PDB and myopathy  ADDIN EN.CITE [49], but it was soon extended to encompass the additional feature of frontotemporal dementia (FTD)  ADDIN EN.CITE [50] and amyotrophic lateral sclerosis (ALS).  Myopathy is the most frequent feature of IBMPFD which occurs in about 90% of individuals. The age at presentation varies widely with a mean age of 42 years and a range of 3-66 years. Involvement of the proximal limb girdle muscles is almost universal but the distal limb muscles and facial muscles may also be involved. Muscle biopsies show evidence of myopathic changes, and prominent intracellular rimmed vacuolar inclusion bodies. Motor neuron involvement is frequent in MSP, affecting more than half of the patients in a one clinical series  ADDIN EN.CITE [57]. About 43% of individuals also have PDB with an average age at onset of 42 years with a range of 29-61 years. The clinical and radiographic features are similar to classical Paget’s disease but with an earlier age at onset. As is the case in classical PDB, patients may or may not be symptomatic. The third component of dementia affects about 37% of individuals with an average age at onset of 54 years and a range of 39 to 62 years. Patients with MSP have a reduced life expectancy with death occurred at an average age of 58 years due to respiratory and cardiac failure. 
Genetics
Mutations of the VCP gene encoding Valosin-Containing Protein were discovered to be a cause of MSP1 by linkage analysis  ADDIN EN.CITE [50] followed by positional cloning  ADDIN EN.CITE [51]. In the original report, six different disease-causing mutations in VCP were identified. However, at the time of writing, 45 different pathogenic VCP mutations have now been identified in patients with MSP (Table 4)  ADDIN EN.CITE [58]. Whilst mutations have been identified throughout the gene, the majority are situated in exons 3-5 which encode the N-terminal domain which is involved in ubiquitin binding and binding of co-factors essential for VCP’s function. Mutations in VCP are estimated to account for about half of all cases of MSP  ADDIN EN.CITE [59], with additional MSP mutations identified in the genes encoding hnRNPA2B1 (MSP2), hnRNPA1 (MSP3), SQSTM1 (MSP4) and Matrin-3 (MSP5) [56]. 








G128A, G128C	4	N-terminal	N387H, N387S, N387T	10	L2
P137L	4	N-terminal	N401S	11	L2
I151V	5	N-Terminal	A439S, A439G, A439P	11	L2




R159H, R159L, R159C, R159G	5	N-terminal	N750S	16	C-terminal
A160P	5	N-terminal			
Pathogenic mutations in VCP that have been described in MSP’s are shown (adapted from Al-Tahan et al  ADDIN EN.CITE [58]). 

Pathophysiology
VCP is a member of the AAA+ (ATPase Associated with diverse cellular Activities) family of proteins. VCP governs an ever-expanding spectrum of ubiquitin-dependent cellular processes, ranging from protein quality control and cellular signaling to organelle biogenesis and elimination [60].  The primary function of VCP is that of a ubiquitin-dependent segregase that uses a variety of adaptor proteins to engage ubiquitinated clients and physically disengage these proteins from multimeric complexes, pull proteins out of membranes, and in some cases unfold client proteins to facilitate proteasomal degradation. This activity of VCP is essential for at least three ubiquitin-dependent modes of protein degradation, including endoplasmic reticulum-associated degradation (ERAD)  ADDIN EN.CITE [61] ubiquitin-dependent autophagy  ADDIN EN.CITE [62] and ribosome quality control  ADDIN EN.CITE [63]. VCP activity is also required for the assembly of the Golgi apparatus and ER [60] as well as mitochondrial fission and clearance of defective mitochondria by mitophagy  ADDIN EN.CITE [64]. Among the nuclear functions dependent upon VCP activity are regulation of DNA damage responses  ADDIN EN.CITE [65] and chromatin-associated protein degradation [60]. Of potential relevance to the PDB component of the disease, VCP is involved in signaling pathways, including degradation of IB  ADDIN EN.CITE [66]. Another essential VCP function, which is particularly interesting in light of the genetic heterogeneity of MSP, is autophagic degradation of stress granules, a type of RNP granule that forms in the cytoplasm in response to translation inhibition  ADDIN EN.CITE [67]. Not only is VCP (linked to MSP1) found in stress granules, but so are at least three additional MSP-linked gene products, including hnRNPA2B1 (MSP2), hnRNPA1 (MSP3) and SQSTM1 (MSP4).
In order to investigate the mechanisms by which VCP mutations cause IBMFPD, Custer et al  ADDIN EN.CITE [68] generated transgenic mice with overexpression of the R155H and A232E mutations in VCP under the control of a cytomegalovirus enhanced beta-actin promoter which drives transgene expression in all tissues. When compared with wild type littermates, the mutant mice developed muscle weakness by about 4 months of age and this was accompanied by accumulation of cytoplasmic aggregates of the TDP-43 protein in combination with ubiquitin in muscle. Behavioural abnormalities were also noted accompanied by accumulation of cytoplasmic aggregates of TDP-43 and ubiquitin in neurons.  Skeletal phenotyping of 13-month-old mice showed evidence of osteopenia with reduced bone volume/total volume, reduced trabecular number and reduced trabecular thickness when compared with wild type littermates. The authors also noted occasional osteosclerotic lesions within the internal cavity of long bones and areas of reduced bone density beneath the growth plate of the distal femur. Histological analysis was not performed to evaluate the nature of these lesions. In order to investigate the effects of the A232E mutation on NFB signaling, wild type and mutant VCP was over expressed in C2C12 myoblastic cells stimulated with TNF. These experiments showed increased NF activation following TNF stimulation in A232E transfected cells as compared with wild type and more rapid clearance of I.  This suggests that the mutant VCP may have an enhanced ability to bind IB and target it for degradation Weihl and colleagues generated transgenic mice with in which the R155H mutation of VCP was driven by a muscle specific promoter  ADDIN EN.CITE [69].  The mutant mice developed muscle weakness from about 6 months of age in association with accumulation of inclusion bodies consisting of ubiquitin and high molecular weight ubiquitinated proteins. The animals did not show the rimmed vacuoles that are characteristic of IBMFPD but did show what the authors referred to as “rimmed cracks” in the sarcoplasm and sarcolemmal regions. In another study Badadani et al generated mice with a knock-in of the R155H mutation  ADDIN EN.CITE [70]. The mice developed muscle weakness by 6 months of age. Histological analysis of muscle revealed vacuolization of the myofibrils with accumulation of TDP-43 and ubiquitin containing cytoplasmic inclusion bodies. The authors also reported finding increased staining of LC3-II in muscle, providing evidence of impaired autophagy. Cytoplasmic TDP-43 and ubiquitin containing inclusions were also found in neurons but the mutant mice did not show evidence of memory impairment. However about 15% had developed seizures by the age of 9 months. Skeletal phenotyping showed no evidence of osteopenia on MicroCT analysis but cortical thickness was increased. There wasn’t clear evidence of PDB-like bone lesions in R155H knock-in mice but evidence of increased osteoclast formation was found in M-CSF and RANKL stimulated bone marrow cultures from the mutant as compared with wild type mice.
The mechanisms of disease in patients with VCP mutations are incompletely understood, but is likely to involve some but not all the ubiquitin-dependent processes that are regulated by VCP.  In cell-based, Drosophila and mouse model systems, disease-causing mutations in VCP do not detectably impair ERAD or organelle assembly  ADDIN EN.CITE [62, 64]. An early report of ERAD impairment in response to over-expression of mutant VCP relied upon a reporter system later learned to be sensitive to autophagy impairment  ADDIN EN.CITE [71]. Indeed, subsequent analyses determined that disease-causing mutations in VCP impair ubiquitin-dependent autophagy  ADDIN EN.CITE [62, 72]. Accumulation of abnormal mitochondria has been observed consistently in animal models harboring mutant VCP mutations  ADDIN EN.CITE [64, 68, 70] and this is likely due to impaired mitophagy  ADDIN EN.CITE [64]. Interestingly, an unbiased screen for genetic modifiers of mutant VCP-related degeneration in Drosophila identified RNA-binding proteins, homologs of hnRNPA1 and hnRNPA2B1 in particular, as strong suppressors  ADDIN EN.CITE [73]. The intersection of these three gene products and SQSTM1 in stress granules, and the impairment of stress granule dynamics observed with defects in these proteins, has drawn particular attention to the role of abnormal stress granules in disease pathogenesis [74]. How mutations in VCP impair some functions but not others is incompletely understood, but quite likely reflects a biased effect on the interaction of VCP with various adaptors  ADDIN EN.CITE [75]. Specifically, the molecular bases of the PDB component of MSP is unknown, but likely reflects hyperactivation of NFB at least in part. 
Management
At the present time management of this disorder involves supportive care only. Bisphosphonates are likely to be of value in managing the PDB component although there is little published information on how well this type of PDB responds to bisphosphonate therapy.
hnRNP associated multisystem proteinopathy
This syndrome was described by Kim and colleagues  ADDIN EN.CITE [6] following genetic analyses of three families with autosomal dominant inheritance of neurodegenerative disease accompanied in some cases by PDB with features that were indistinguishable from VCP-related MSP  ADDIN EN.CITE [6] However, all patients had been screened for VCP mutations and none were found, triggering the search for an alternative causal gene.  
Clinical features
Affected members of one family (Family 1) exhibited autosomal dominant inheritance of myopathy, PDB, cognitive impairment and amyotrophic lateral sclerosis (ALS) in various combinations. Clinical evaluation of families 1 and 2 showed evidence of a myopathy characterised by atrophic myofibrils, central nuclear and rimmed vacuoles, typical of inclusion body myopathy. More detailed analysis of some affected patients showed redistribution of hnRNPA2B1, hnRNPA1 and TPD-43 proteins from their normal location in the nucleus to the cytoplasmic inclusion bodies which also contained ubiquitin and p62 in limited amounts. Similar findings had previously been reported in sporadic inclusion body myopathy (IBM) [76] and in IBM associated with VCP mutations. 
Genetics
The affected members of family 1 were found to share a missense mutation in the hnRNPA2B1 gene causing an amino acid change from aspartic acid to valine at position 290 (D290V) and 302 (D320V) in different isoforms of the protein generated by differences in splicing. In a second family (Family 2), where PDB and myopathy were inherited in an autosomal dominant manner, a missense mutation in the hnRNPA1 gene as found causing an amino acid change from aspartic acid to valine at position 262 (D252V) and 214 (D314V) in different isoforms. Affected members of another family with autosomal dominant inheritance of ALS (Family 3) were found to have an amino acid substitution to N at the same residue (D262N/D314N). The terms MSP2 and MSP3 have been used to describe the syndromes caused by mutations in hnRNPA2B1 and hnRNPA1 respectively  ADDIN EN.CITE [77]. 
Pathophysiology
In order to gain an insight into the mechanisms by which these mutations were pathogenic, the authors conducted a series of bioinformatic and functional studies. Disease-causing mutations in hnRNPA2B1 and hnRNPA1 were found to impact intrinsically disordered protein segments that are common to many members of the hnRNP family, including TDP-43, TIA1, hnRNPDL and FUS  ADDIN EN.CITE [6]. Indeed, ALS-, FTD- and myopathy-causing mutations were subsequently identified in these hnRNPs [78]. The intrinsically disordered protein segments found in members of the hnRNP family were found to support higher order assembly into amyloid-like fibrils in vitro and, indeed, this property is consistently enhanced by disease-causing mutations [78]. In living cells, higher order assembly of these disordered segments is important in the formation and liquid properties of membrane-less organelles that arise though phase transitions – most notably RNA granules [79]. Indeed, impairment of the dynamics of RNA granules appears to be a unifying principle underlying the degeneration observed in MSP downstream of all genetic etiologies. At the present time, the mechanisms by which these mutations cause the PDB component of the syndrome remains to be established although it is intriguing to speculate that impaired stress granule dynamics may also impact signaling through proteins like NFB [18]. 
Management
At the present time management of this disorder involves supportive care only. Bisphosphonates are likely to be of value in managing the PDB component although there is little published information on how well this type of PDB responds to bisphosphonate therapy.
PDB-associated genes and multisystem proteinopathy
Although most patients with SQSTM1 mutations develop PDB in the absence of neurological symptoms, it has become apparent that missense mutations in SQSTM1 can also cause neuromuscular degeneration with features of multisystem proteinopathy (termed MSP4) either in the presence or absence of PDB  ADDIN EN.CITE [77]. 
Clinical presentation
The clinical  presentation of SQSTM1-associated MSP is wide and may include sporadic and familial amyotrophic sclerosis [80], frontotemporal dementia with or without ALS  ADDIN EN.CITE [81], isolated inclusion body myopathy  ADDIN EN.CITE [77] and inclusion body myopathy with PDB  ADDIN EN.CITE [82]. 
Genetics
At the present time it is unclear why some patients develop PDB, whereas others develop myopathy, ALS or frontotemporal dementia. A plausible reason for the differences in clinical presentation of patients with SQSTM1 mutations suggested by Bucelli  ADDIN EN.CITE [77] is that inheritance of susceptibility alleles of other genes that predispose to individual components of the syndrome may determine which phenotypes are expressed.  The strongest evidence for the importance of a gene-gene interaction in determining which phenotype is predominant in MSP comes from the observations by Lee and colleagues  ADDIN EN.CITE [83] who reported that inheritance of the N357S variant of the NIA1 gene in combination with various mutations affecting the UBA domain of SQSTM1 result in a distal myopathy whereas the same NIA1 variant is not pathogenic in the absence of SQSTM1 mutations. Furthermore, SQSTM1 mutations in the absence of NIA1 mutations do not cause a distal myopathy. 
Pathophysiology
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Figure 1: Insertion mutations of TNFRSF11A














Under normal circumstances the RANK signal peptide is cleaved as it emerges from the endoplasmic reticulum (ER) and the receptor migrates to the cell surface where it can be activated by RANKL causing NFB activation through the classical pathway (left side of figure). Insertion mutations affecting the signal peptide of RANK result in failure of signal peptide cleavage causing the abnormal protein to accumulate in the ER with activation of NFB through the unfolded protein response (UPR) (right side of figure).  
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